Science
FDA Reviews Ensitrelvir as First Oral Pill to Prevent COVID-19 After Exposure
The drug ensitrelvir, already approved in Japan, showed a 67% reduction in infection risk during Phase 3 trials for post-exposure prophylaxis.
Topic
2 stories on covid-19, across Science.
The drug ensitrelvir, already approved in Japan, showed a 67% reduction in infection risk during Phase 3 trials for post-exposure prophylaxis.
A phase 3 trial of the drug ensitrelvir, known as Xocova, showed a 67% reduction in COVID-19 infection risk for people treated after exposure.